This circumsporozoite protein (CSP)–based vaccine showed an encouraging 50% sterile protection in malaria-naive adult volunteers [5] but only reduced clinical and severe disease by 30%–45% in children in malaria-endemic areas [6, 7]. The gene discussed is DNAJC5; the disease is malaria.